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Sir: Telomerase reverse transcriptase (TERT) is a
ribonucleoprotein involved in maintaining the length
of telomeres. In the absence of TERT expression, dif-
ferentiated cells can only divide a finite number of
times before undergoing cellular senescence – often
referred to as the Hayflick limit. Mutations within the
promoter region of TERT that create consensus bind-
ing sequences for ETS family transcription factors are
a common mechanism by which neoplastic cells
increase TERT expression and overcome this limit.1
TERT promoter mutations are common in many can-
cer types, including 60–80% of urothelial carcinomas
(UC).2,3 Given the high frequency of these mutations
in UC and the absence of these mutations in non-neo-
plastic/benign mimics of UC,4 TERT promoter muta-
tions may serve as potential biomarkers for
monitoring patients with a history of malignancy.
Multiple studies have reported detecting TERT muta-
tions in specimens used commonly for monitoring UC
patients, such as urine.2,3,5 However, in order to be a
reliable marker of residual/recurrent disease, TERT
mutation status must be a stable and uniform attri-
bute shared among all neoplastic cells and preserved
over time. To our knowledge, no previous study has
compared TERT promoter genotypes within spatial,
temporal and morphologically distinct components of
UC.
In order to evaluate the stability and uniformity of
TERT mutations within a given UC, we developed an
allele-specific polymerase chain reaction (PCR) assay
targeting the most common TERT promoter muta-
tions: c.-146C>T (Chr.5:1295250C>T), c.-124C>T
(Chr.5:1295228C>T), c.-138_139CC>TT (Chr.5:1295
242_1295243CC>TT) and c.-124_125CC>TT (Chr.5:
1295228_1295229CC>TT). Using this assay, we
evaluated 102 DNA samples extracted from formalin-
fixed paraffin-embedded tissues from 50 patients with
invasive, high-grade UC. The age range of the
patients in this cohort was 50–88 years, with the
majority of the patients demonstrating pathological
stage pT2b–pT4 at the time of cystectomy.6 In order
to determine if TERT mutation status varies among
spatially distinct regions of UC, microdissection was
performed to isolate distinct regions within the same
block for 19 cases and within separate blocks for 20
cases, including three metastatic foci (Figure 1, Sup-
porting information, Table S1). For 26 UC patients,
microdissection was performed in order to evaluate
conventional UC and components with divergent dif-
ferentiation separately, including sarcomatoid (five),
nested and tubular (eight), micropapillary (seven),
squamous (nine), glandular (two), single cell/diffuse/
plasmacytoid (two) and neuroendocrine (one). The
variant morphologies were assigned as instructed by
the WHO classification of tumours of the urinary system
and male genital organs, 4th edition.7 To evaluate the
temporal stability of TERT mutations, specimens from
multiple time-points were evaluated for 11 patients
(mean: 2.9 years apart; range: 0.2–8.8 years). Four-
teen single-sample cases (conventional UC and diver-
gent differentiation) were also included to establish
the frequency of TERT promotor mutations in com-
parison with previous studies.
Overall, TERT mutations were found in in 76.0%
(38 of 50) of UC cases, similar to previous studies;2,3
-124C>T was the most common (34 patients), fol-
lowed by -146C>T (seven patients) and a single
instance of -138_-139CC>TT. TERT status was con-
served temporally in all cases evaluated. For mor-
phologically and spatially disparate components, we
found TERT mutation status to be conserved per-
fectly in all but one case. This case harboured a -
138_-139CC>TT mutation within conventional UC
and a -124C>T mutation within a separate block
showing squamous differentiation. These results
were confirmed after re-extraction and repeated
TERT testing. Further evaluation of these two speci-
mens using the Ion AmpliSeq Cancer Hotspot
Panel showed that both components shared a
PIK3CA E542K mutation. However, a PTEN R130Q
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mutation was present with the squamous compo-
nent, but not in the conventional UC. These results
suggest that while these two components are related
clonally to one another, each component represents
a morphologically and molecularly distinct subclonal
population.
In conclusion, TERT promoter mutations are con-
served in the majority of morphologically, spatially
and temporally distinct components of a given
urothelial carcinoma. These findings corroborate the
notion that components of UC with divergent differ-
entiation remain related clonally to the conven-
tional UC. In rare cases, spatially and
morphologically distinct components of UC also
show differing TERT genotypes. In this study, we
showed that these genotypical differences reflect
subclonal populations (intratumoral heterogeneity)
within some cases of UC. TERT promoter mutations
represent secondary alterations in the pathogenesis
of UC and other neoplasms.1,8 That TERT status is
conserved spatially and temporally in most cases
reflects the fact that these secondary mutations
generally occur early in the pathogenesis of UC.3
Overall, TERT promoter mutation status is a stable
biomarker in most cases and may therefore be use-
ful in disease monitoring.
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Figure 1. An example of one patient with urothelial carcinoma (UC) in which microdissection was performed in order to isolate DNA from
different components, including conventional invasive high-grade UC in the posterior bladder wall, squamous differentiation in the bladder
neck, urothelial carcinoma in-situ in the bladder dome, left lateral wall and prostatic urethra and squamous differentiation in a left pelvic
lymph node metastasis. Identical TERT c.-124C>T mutations were identified in all components.
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Sir: Phyllodes tumours (PT) of the male urogenital
tract are rare; to date, fewer than 100 cases have
been described in the prostate, and fewer than 15 in
the seminal vesicle.1 They display histological features
and clinical behaviour similar to PTs of the female
breast; the lesions may be cured by surgical resection
but a large proportion exhibit local recurrence, and
cases of direct invasion into adjacent organs and
widespread metastasis have been reported.2 Although
no single morphological feature is reliably predictive
of prognosis, a combined assessment may be used for
grading and prognostication, as in the breast.2 We
encountered a primary urinary bladder PT which, to
our knowledge, is the first such case described in a
human.
A 54-year-old man underwent partial cystectomy
for a recurrent bladder tumour in September 2015 at
our institution. He had presented initially with
haematuria 14 years previously; since that time, he
had had multiple cystoscopic resections of recurrent
polypoid masses in the bladder dome. In view of the
multiple episodes of recurrence, the large size of the
lesion and progression on serial imaging, partial cys-
tectomy was performed. This showed a tumour com-
posed of broad, oedematous papillary projections,
tan/grey in colour, with a firm and homogeneous cut
surface.
Histological sections showed a polypoid stromo-
epithelial tumour arising from the mucosal compart-
ment and arranged in broad-based papillae, many of
which exhibited a club-shaped or cloverleaf-type
appearance and clefting (Figure 1A). Subepithelial
condensation of stromal cells was noted (Figure 1B).
The stromal cells were spindled and stellate in appear-
ance, did not show conspicuous cytological atypia,
and mitotic figures were not identified (Figure 2A).
Focal surface calcification and minimal superficial
necrosis were present, the latter of which was related
A
B
Figure 1. A, Low-power view demonstrating the polypoid, exo-
phytic tumour projecting from the mucosal surface of the bladder.
B, High-power view demonstrating subepithelial condensation of
stromal cells.
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